Xellia Pharmaceuticals, a specialty pharmaceutical company focusing on providing anti-infective treatments, is expanding its Raleigh, North Carolina site to enable the relocation of its North American headquarters from Grayslake, Illinois. The decision to move its North American headquarters from Illinois to North Carolina follows Xellia’s acquisition of a lyophilized vial manufacturing facility from Fresenius Kabi in 2014. The move combines the company’s North American commercial function with the manufacturing facility into one location, forming the new headquarters for the territory. Staff based at the Grayslake site have begun a phased relocation.

Xellia is a developer, manufacturer,and supplier of fermented and semi-synthetic active pharmaceutical ingredients (APIs) and injectable finished dosage forms (FDFs) to the pharmaceutical industry. Headquartered in Copenhagen, Denmark, Xellia has global facilities, including operational and manufacturing capabilities in Denmark, the US, Hungary, and China, and currently employs more than 1,000 people. Xellia is a supplier of vancomycin and colistimethate sodium for treating multi-drug resistant (MDR) bacterial infections across Gram-positive and Gram-negative species. Xellia is also developing novel antibiotics effective against MDR Gram-negative bacteria in a development project with SINTEF Materials and Chemistry (Trondheim) and the Statens Serum Institut (Copenhagen), supported by a grant from the Research Council of Norway.

Since July 2013, Xellia has been wholly owned by Novo A/S, the holding company of the Novo Group. Since its spin-out from Alpharma Inc. in 2008, Xellia's management and international investor 3i have transformed the business from an API manufacturer to a specialty pharmaceutical company focused on antiinfective products.

Source: Xellia Pharmaceuticals